Oxaliplatin-induced neuropathy and colo-rectal cancer patient’s quality of life: Practical lessons from a prospective cross-sectional, real-world study

Table 2 Patient’s status at the time of study enrollment

Treatment status
Still going on	35.7%
Stopped due to neuropathy	30.8%
Stopped due to toxicity	16.7%
Finished chemotherapy	16.8%
Types of toxicity
Neuropathy	30.8%
Hematologic	28.2%
Digestive	12.4%
Dermatologic	3.5%
Mixed	25.1%